Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and chemotherapy for pediatric relapsed/refractory ALL
NCT03515200Phase 1Terminated
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in acute lymphoblastic leukemia (ALL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Maximum tolerated dose of palbociclib plus chemotherapy at 40 days. Started Apr 2018; status: terminated.
02
Drugs
palbociclib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03515200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515200.